KalVista Pharmaceuticals, Inc.KALVNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+62.1%
5Y CAGR+50.9%
Year-over-Year Change
Selling, general, and administrative expenses
3Y CAGR
+62.1%/yr
vs +29.4%/yr prior
5Y CAGR
+50.9%/yr
Recent acceleration
Acceleration
+32.8pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
7.8x
Strong expansion
Streak
8 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $130.34M | +12.1% |
| 2025 | $116.29M | +114.2% |
| 2024 | $54.28M | +77.4% |
| 2023 | $30.59M | +15.7% |
| 2022 | $26.45M | +59.0% |
| 2021 | $16.64M | +27.7% |
| 2020 | $13.03M | +19.2% |
| 2019 | $10.93M | +23.3% |
| 2018 | $8.86M | -20.7% |
| 2017 | $11.18M | - |